Perrigo Boosts 2022 Guidance Shifting From Changing Organization To Delivering Results
Executive Summary
“We said we would start growing this company ... and this is the year to do it,” says CERO Murray Kessler. With nearly 11% net sales growth for its Americas business leading nearly 10% overall Q1 growth, Perrigo raises full-year guidance for net sales growth to 8% to 9%, up earlier 7% to 8%.
You may also be interested in...
Revolving Door Of Executive Changes At Perrigo As Firm Revises Its Expectations Up
Perrigo is set to welcome a new chief financial officer and corporate security head as it rounds up a fairly successful first quarter.
Weighing Shortage Risk, FDA Clears Releasing Metabolic Formulas Made At Abbott’s Closed Plant
With Michigan facility closed as cause of bacterial contamination is investigated, FDA announces “has no objection” to Abbott releasing specialty and metabolic formulas “to individuals needing urgent, life-sustaining supplies” on a case-by-case basis.
Silcock’s Work As Perrigo CFO Is Done With Firm Transitioned Entirely To Self-Care
With Raymond Silcock’s work at Perrigo linked to CEO Murray Kessler’s time with the firm and with the two working together previously as CFO and CEO at a tobacco firm, whether Kessler continues at the helm could become a topic of shareholder interest.